At the 2025 annual conference of ANZSEV – the Australian and New Zealand Society of Extracellular Vesicles – VivaZome’s Senior Translational Scientist, Dr Smriti Krishna, presented “Extracellular vesicles improve functional outcomes after moderate traumatic brain injury (TBI) in a preclinical model”.

Dr Krishna presented data demonstrating that in preclinical studies at the University of Queensland, VivaZome’s EVs improved motor function 24 hrs post-TBI, while, in the epilepsy arm, animals treated with VivaZome’s EVs exhibited a trend toward reduced seizure frequency and increased latency to generalized seizures. These proof-of-concept findings highlight VivaZome EVs as a promising treatment for brain injury.  Mechanistically, VivaZome’s EVs are enriched in miRNAs with known anti-inflammatory potential which may help modulate the neuroinflammatory pathways and support recovery.

Clinically, TBI triggers uncontrolled, severe inflammation which disrupts brain repair and causes further brain damage leaving 10-15% of survivors with post-traumatic epilepsy. Dr Krishna highlighted that, every year, >300,000 Australians and 2.5 million Americans suffer a brain injury, which represents a substantial economic burden on healthcare systems.

To read the abstract of Dr Krishna’s talk, click here